Belgian biotech Galapagos (NASDAQ:GLPG) announced a major restructuring drive on Wednesday, with plans to amend its 10-year ...

Leerink Partners analyst Faisal Khurshid has maintained their neutral stance on GLPG stock, giving a Hold rating on December 23.Stay Ahead of ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Galapagos (GLPG – Research Report) today and set a price target ...

Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our c Galapagos ( AMS:GLPG ) Third Quarter 2024 ...

Check the time stamp on this data. Updated AI-Generated Signals for Galapagos Nv (GLPG) available here: GLPG. Type a few ...

Galapagos plans to split into two entities by mid-2025, focusing its core business on cell therapies while spinning off a new ...

In trading on Thursday, shares of Galapagos NV (Symbol: GLPG) crossed above their 200 day moving average of $28.06, changing hands as high as $28.22 per share. Galapagos NV shares are currently ...

To get a sense of who is truly in control of Galapagos NV (AMS:GLPG), it is important to understand the ownership structure of the business. With 56% stake, retail investors possess the maximum ...

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain ...